Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ESC 2026
Effects of finerenone in patients with hypertensive nephropathy
In FIND-CKD participants with hypertensive nephropathy, finerenone versus placebo:
- Slowed CKD progression defined by total eGFR slope.
- Reduced the risk of the composite kidney–CV outcome.
- Reduced systolic blood pressure and albuminuria at 6 months, an effect sustained throughout the treatment period.
Safety events were consistent with the overall trial population.
Hyperkalaemia occurred more frequently with finerenone than with placebo, but hospitalisation and permanent treatment discontinuation due to hyperkalaemia were uncommon.
This prespecified subgroup analysis supports blockade of mineralocorticoid receptor overactivation as a therapeutically relevant treatment pathway in individuals with non-diabetic CKD due to hypertensive nephropathy.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
